Cardiology: Clinical Studies Open For Enrollment
Eligibility
- Symptomatic Hypertrophic cardiomyopathy
- Hemoglobin at least 10 g/dL at screening
- No moderate-severe valvular aortic stenosis and/or regurgitation
Enrollment Status: Enrolling
Study Information
ClinicalTrials.gov | NCT05186818
Principal Investigator
Dr. Srihari Naidu
Contact for Study Screening
Erida.Castro@wmchealth.org and FNU.Namrata@wmchealth.org
PROTOCOL CY 6022 AN OPEN-LABEL STUDY OF CK3773274 FOR PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY (HCM)
Eligibility
- Symptomatic Hypertrophic cardiomyopathy
- Any acute or serious comorbid
Enrollment Status: Enrolling
Study Information
ClinicalTrials.gov | NCT04848506
Principal Investigator
Dr. Srihari Naidu
Contact for Study Screening
Erida.Castro@wmchealth.org and FNU.Namrata@wmchealth.org
Observational Study Protocol CV027-012 DELIVER INSIGHTS IN HYPERTROPHIC CARDIOMYOPATHY AND OBSERVATIONAL OUTCOMES IN REAL WORLD (DISCOVER-HCM): UNITED STATES PROSPECTIVE REGISTRY STUDY
Eligibility
- Diagnosis of obstructive Hypertrophic cardiomyopathy
Enrollment Status: Enrolling
Study Information
ClinicalTrials.gov | NCT05489705
Principal Investigator
Dr. Srihari Naidu
Contact for Study Screening
Erida.Castro@wmchealth.org and FNU.Namrata@wmchealth.org
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)
Eligibility
- Atherosclerotic Cardiovascular Disease by the history of either Myocardial infarction or Coronary revascularization.
- No severe renal dysfunction.
Enrollment Status: Enrolling
Study Information
ClinicalTrials.gov | NCT05581303
Principal Investigator
Dr. Diwakar Jain
Contact for Study Screening
Erida.Castro@wmchealth.org and FNU.Namrata@wmchealth.org